Context
Swertia mussotii
Franch. (Gentianaceae) is a source of the traditional Tibetan medicine, ZangYinChen, and is used to treat chronic hepatitis and many types of jaundice.
Objective
This study explored the therapeutic effects and mechanism of
S. mussotii
on non-alcoholic fatty liver disease in diet-induced hypercholesterolaemia.
Materials and methods
After a week of adaptive feeding, 32 Sprague-Dawley rats were divided into four groups: (1) Control, (2) Control-S, (3) Model, and (4) Model-S. During the 12 experimental weeks, we established the Model using a high-fat diet. Control-S and Model-S were given 1.0 g/kg
S. mussotii
water extract via gavage starting in the fifth week until the end of experiment.
Results
When compared with Model rats, the
S. mussotii
water extract led to a reduction in high-density lipoproteins (43.9%) and albumin (13.9%) and a decrease in total cholesterol (54.0%), triglyceride (45.6%), low-density lipoproteins (8.6%), aspartate aminotransferase (11.0%), alanine aminotransferase (15.5%), alkaline phosphatase (19.1%), total protein (6.4%), and glucose (20.8%) in serum. A reduction in three cytokines (IL-1β, IL-6, and TNFα) was detected. Histopathological examination showed that liver steatosis was significantly relieved in
S. mussotii
-treated high-fat diet rats.
S. mussotii
also caused a downregulation in the expression of TLR4 (43.2%), MyD88 (33.3%), and a decrease in phosphorylation of NF-κB.
Discussion and conclusions
Our findings indicate that
S. mussotii
may act as a potential anti-inflammation drug via inhibition of the TLR4/MyD88/NF-κB pathway. Further
in vivo
and
in vitro
studies are needed to validate its potential in clinical medicine.